- Home
- PTC vs WAT Comparison
PTC vs WAT Comparison
Compare PTC & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTC
- WAT
- Stock Information
- Founded
- PTC 1985
- WAT 1958
- Country
- PTC United States
- WAT United States
- Employees
- PTC N/A
- WAT N/A
- Industry
- PTC Computer Software: Prepackaged Software
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- PTC Technology
- WAT Industrials
- Exchange
- PTC Nasdaq
- WAT Nasdaq
- Market Cap
- PTC 20.2B
- WAT 17.8B
- IPO Year
- PTC 1989
- WAT 1995
- Fundamental
- Price
- PTC $205.11
- WAT $295.50
- Analyst Decision
- PTC Buy
- WAT Hold
- Analyst Count
- PTC 13
- WAT 14
- Target Price
- PTC $209.77
- WAT $374.07
- AVG Volume (30 Days)
- PTC 835.0K
- WAT 577.5K
- Earning Date
- PTC 11-05-2025
- WAT 10-31-2025
- Dividend Yield
- PTC N/A
- WAT N/A
- EPS Growth
- PTC 73.27
- WAT 10.77
- EPS
- PTC 4.25
- WAT 11.09
- Revenue
- PTC $2,471,978,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- PTC $13.64
- WAT $7.19
- Revenue Next Year
- PTC $7.73
- WAT $6.40
- P/E Ratio
- PTC $48.36
- WAT $26.70
- Revenue Growth
- PTC 11.42
- WAT 5.89
- 52 Week Low
- PTC $133.38
- WAT $275.05
- 52 Week High
- PTC $219.69
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- PTC 44.60
- WAT 47.98
- Support Level
- PTC $202.26
- WAT $288.90
- Resistance Level
- PTC $207.26
- WAT $303.24
- Average True Range (ATR)
- PTC 4.15
- WAT 8.76
- MACD
- PTC -1.65
- WAT 0.63
- Stochastic Oscillator
- PTC 18.53
- WAT 37.96
About PTC PTC Inc.
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America and Europe.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.